..... moves to amend H.F. No. 3100, the second engrossment, as follows:

1.1

1.2	Page 2, line 6, after "(3)" insert "state that the contract is subject to section 13.05,
1.3	subdivision 11, and"
1.5	Subdivision 11, and
1.4	Page 8, line 3, after the period, insert "In addition to notices and disclosures required
1.5	under section 62V.06, subdivision 6, the board must provide program applicants with notice
1.6	of what information about the applicant the board may share with drug manufacturers."
1.7	Page 8, after line 32, insert:
1.8	"(e) A manufacturer participating in the program:
1.9	(1) is subject to section 13.05, subdivision 6, as if it had entered into a contract with the
1.10	board of directors of MNsure;
1.11	(2) must maintain the privacy of all data received as part of the program; and
1.12	(3) is prohibited from selling, sharing, or disseminating data received as part of the
1.13	program, except as necessary to fulfill the requirements of the program."
1.14	Page 8, line 33, delete "(a) All data collected, created, or maintained by the board under
1.15	this" and insert "(a) All data collected, created, received, maintained, or disseminated by
1.16	the board under this section related to applicants, eligible individuals, and program
1.17	participants:"
1.18	Page 8, delete line 34
1.19	Page 9, delete lines 1 to 3 and insert:
1.20	"(1) is classified as private data on individuals as defined in section 13.02, subdivision
1.21	<u>12;</u>
1.22	(2) may be shared with manufacturers participating in the program, but only with patient
1.23	consent and to the extent necessary for program operation;

02/17/20 05:23 pm HOUSE RESEARCH RC/JF H3100A7-1

- 2.1 (3) is subject to section 62V.06, subdivisions 6, 8, and 9; and
- (4) may be retained by the board for no longer than ten years."